<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00115778</url>
  </required_header>
  <id_info>
    <org_study_id>AAAB0431</org_study_id>
    <nct_id>NCT00115778</nct_id>
  </id_info>
  <brief_title>Intravenous Immunoglobulin (IVIG) in Lung Transplantation</brief_title>
  <official_title>IVIG for Acquired Immunodeficiency in Lung Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if intravenous immunoglobulin (IVIG) can prevent
      bacterial infections in lung transplant patients with low serum levels of immunoglobulin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An increased risk of infection despite intensive antimicrobial prophylaxis is a
      well-recognized complication of lung transplantation. Recent evidence suggests that
      immunosuppressive therapy after solid organ transplantation may lead to humoral
      immunodeficiency due to hypogammaglobulinemia (HGG). In lung transplant recipients with HGG,
      IVIG therapy offers the potential to significantly decrease the incidence and severity of
      infections, thereby reducing morbidity and potentially mortality.

      Comparison: The investigators are conducting a randomized clinical trial of IVIG versus
      placebo for lung transplant patients with severe HGG to see if IVIG decreases the number of
      bacterial infections in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Clinically Diagnosed Bacterial Infections During the Treatment Period</measure>
    <time_frame>3 month</time_frame>
    <description>The number of events occurring during the treatment period. The data will be presented by the occurrence during the IVIG vs. the placebo treatment period, regardless of the order that the treatment was received. Only the clinically diagnosed bacterial infections will be counted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Clinically Diagnosed Viral Infections</measure>
    <time_frame>3 month</time_frame>
    <description>This is to measure the effect of IVIG on viral infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospital Admissions</measure>
    <time_frame>3 month</time_frame>
    <description>This is to measure the effect of IVIG on hospitalizations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Antibiotic Initiation</measure>
    <time_frame>3 month</time_frame>
    <description>This is to measure the effect of IVIG on the use of antibiotics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Clinically Diagnosed Fungal Infection</measure>
    <time_frame>3 months</time_frame>
    <description>This is to measure the effect of IVIG on fungal infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Lymphocytic Bronchiolitis</measure>
    <time_frame>3 months</time_frame>
    <description>This is to measure the effect of IVIG on lung function.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Hypogammaglobulinemia</condition>
  <condition>Lung Transplantation</condition>
  <arm_group>
    <arm_group_label>First IVIG, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants will receive three doses of IVIG given four weeks apart over 12 weeks followed by a twelve-week washout and then three doses of placebo over 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First Placebo, then IVIG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants will receive three doses of 0.1% albumin solution (placebo) given four weeks apart over 12 weeks followed by a twelve-week washout and then three doses of IVIG over 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVIG</intervention_name>
    <description>10% Caprylate/Chromatography Purified Intravenous Immunoglobulin 400 mg/kg IV every 4 weeks</description>
    <arm_group_label>First IVIG, then Placebo</arm_group_label>
    <arm_group_label>First Placebo, then IVIG</arm_group_label>
    <other_name>Immune globulin intravenous</other_name>
    <other_name>Gamunex</other_name>
    <other_name>Intravenous immunoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.1% Albumin in an equal volume to the investigational product</description>
    <arm_group_label>First IVIG, then Placebo</arm_group_label>
    <arm_group_label>First Placebo, then IVIG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lung transplant recipients &gt; 3 months after transplant surgery

          -  Immunoglobulin G (IgG) &lt; 500 mg/dL

          -  Stable medical regimen

        Exclusion Criteria:

          -  Acute rejection

          -  Active infection

          -  Contraindication to IVIG

          -  Pregnancy

          -  Recent thrombotic event
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selim M Arcasoy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Presbyterian Hospital Lung Transplant Program</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lederer DJ, Philip N, Rybak D, Arcasoy SM, Kawut SM. Intravenous immunoglobulin for hypogammaglobulinemia after lung transplantation: a randomized crossover trial. PLoS One. 2014 Aug 4;9(8):e103908. doi: 10.1371/journal.pone.0103908. eCollection 2014.</citation>
    <PMID>25090414</PMID>
  </results_reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 26, 2005</study_first_submitted>
  <study_first_submitted_qc>June 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2005</study_first_posted>
  <results_first_submitted>June 14, 2011</results_first_submitted>
  <results_first_submitted_qc>February 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2019</results_first_posted>
  <last_update_submitted>February 12, 2019</last_update_submitted>
  <last_update_submitted_qc>February 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Selim Arcasoy</investigator_full_name>
    <investigator_title>Dickinson W. Richards, Jr. Professor of Medicine (in Pediatrics) at the Columbia University Medical Center, Dept of Medicine Pulmonary</investigator_title>
  </responsible_party>
  <keyword>Hypogammaglobulinemia</keyword>
  <keyword>Lung Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agammaglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Eleven subjects were eligible and randomized, and 10 completed all study assessments. One subject discontinued the interventions because of inability to comply with the schedule of study visits. 10 subjects are needed to detect a reduction in the mean number of bacterial infections/patient by one standard deviation over three months with 80% power.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Placebo Then IVIG</title>
          <description>Study participants consented to receive three doses of 0.1% albumin solution (placebo) given four weeks apart over 12 weeks (period 1) followed by a twelve-week washout and then three doses of IVIG over 12 weeks (period 2).
Period 1 (12 weeks) Washout period (12 weeks) Period 2 (12 weeks)
Analysis: modified intention-to-treat</description>
        </group>
        <group group_id="P2">
          <title>Group: 2 IVIG Then Placebo</title>
          <description>Study participants consented to receive three doses of IVIG given four weeks apart over 12 weeks (period 1) followed by a twelve-week washout and then three doses of placebo over 12 weeks (period 2).
Period 1 (12 weeks) Washout period (12 weeks) Period 2 (12 weeks)
Analysis: modified intention-to-treat</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Study participants consented to receive three doses of IVIG (or 0.1% albumin solution (placebo)) given four weeks apart followed by a twelve-week washout and then three doses of placebo (or IVIG).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="28" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Clinically Diagnosed Bacterial Infections During the Treatment Period</title>
        <description>The number of events occurring during the treatment period. The data will be presented by the occurrence during the IVIG vs. the placebo treatment period, regardless of the order that the treatment was received. Only the clinically diagnosed bacterial infections will be counted.</description>
        <time_frame>3 month</time_frame>
        <population>The crossover design, in which each subject serves as his or her own control, allows sufficient power for the detection of a clinically significant effect of IVIG with only a small number of patients. A sample size of 10 patients in a crossover trial has more power to detect differences than double the sample size using a parallel design.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants Receiving IVIG During Period 1 or Period 2</title>
            <description>Study participants received three doses of IVIG first (Period 1) or second (Period 2 - after a twelve-week washout).</description>
          </group>
          <group group_id="O2">
            <title>Participants Receiving Placebo During Period 1 or Period 2</title>
            <description>Study participants received three doses of placebo first (Period 1) or second (Period 2 - after a twelve-week washout).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Clinically Diagnosed Bacterial Infections During the Treatment Period</title>
          <description>The number of events occurring during the treatment period. The data will be presented by the occurrence during the IVIG vs. the placebo treatment period, regardless of the order that the treatment was received. Only the clinically diagnosed bacterial infections will be counted.</description>
          <population>The crossover design, in which each subject serves as his or her own control, allows sufficient power for the detection of a clinically significant effect of IVIG with only a small number of patients. A sample size of 10 patients in a crossover trial has more power to detect differences than double the sample size using a parallel design.</population>
          <units>Infections</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Clinically Diagnosed Viral Infections</title>
        <description>This is to measure the effect of IVIG on viral infections.</description>
        <time_frame>3 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants Receiving IVIG During Period 1 or Period 2</title>
            <description>Study participants received three doses of IVIG first (Period 1) or second (Period 2 - after a twelve-week washout).</description>
          </group>
          <group group_id="O2">
            <title>Participants Receiving Placebo During Period 1 or Period 2</title>
            <description>Study participants received three doses of placebo first (Period 1) or second (Period 2 - after a twelve-week washout).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Clinically Diagnosed Viral Infections</title>
          <description>This is to measure the effect of IVIG on viral infections.</description>
          <units>Number of Infections</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospital Admissions</title>
        <description>This is to measure the effect of IVIG on hospitalizations.</description>
        <time_frame>3 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants Receiving IVIG During Period 1 or Period 2</title>
            <description>Study participants received three doses of IVIG first (Period 1) or second (Period 2 - after a twelve-week washout).</description>
          </group>
          <group group_id="O2">
            <title>Participants Receiving Placebo During Period 1 or Period 2</title>
            <description>Study participants received three doses of placebo first (Period 1) or second (Period 2 - after a twelve-week washout).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospital Admissions</title>
          <description>This is to measure the effect of IVIG on hospitalizations.</description>
          <units>Admissions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Antibiotic Initiation</title>
        <description>This is to measure the effect of IVIG on the use of antibiotics.</description>
        <time_frame>3 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants Receiving IVIG During Period 1 or Period 2</title>
            <description>Study participants received three doses of IVIG first (Period 1) or second (Period 2 - after a twelve-week washout).</description>
          </group>
          <group group_id="O2">
            <title>Participants Receiving Placebo During Period 1 or Period 2</title>
            <description>Study participants received three doses of placebo first (Period 1) or second (Period 2 - after a twelve-week washout).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Antibiotic Initiation</title>
          <description>This is to measure the effect of IVIG on the use of antibiotics.</description>
          <units>Uses of antibiotics</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Clinically Diagnosed Fungal Infection</title>
        <description>This is to measure the effect of IVIG on fungal infections.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants Receiving IVIG During Period 1 or Period 2</title>
            <description>Study participants received three doses of IVIG first (Period 1) or second (Period 2 - after a twelve-week washout).</description>
          </group>
          <group group_id="O2">
            <title>Participants Receiving Placebo During Period 1 or Period 2</title>
            <description>Study participants received three doses of placebo first (Period 1) or second (Period 2 - after a twelve-week washout).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Clinically Diagnosed Fungal Infection</title>
          <description>This is to measure the effect of IVIG on fungal infections.</description>
          <units>Infections</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Lymphocytic Bronchiolitis</title>
        <description>This is to measure the effect of IVIG on lung function.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants Receiving IVIG During Period 1 or Period 2</title>
            <description>Study participants received three doses of IVIG first (Period 1) or second (Period 2 - after a twelve-week washout).</description>
          </group>
          <group group_id="O2">
            <title>Participants Receiving Placebo During Period 1 or Period 2</title>
            <description>Study participants received three doses of placebo first (Period 1) or second (Period 2 - after a twelve-week washout).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Lymphocytic Bronchiolitis</title>
          <description>This is to measure the effect of IVIG on lung function.</description>
          <units>Instances of bronchiolitis</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Participants Receiving IVIG During Period 1 or Period 2</title>
          <description>Study participants received three doses of IVIG first (Period 1) or second (Period 2 - after a twelve-week washout).</description>
        </group>
        <group group_id="E2">
          <title>Participants Receiving Placebo During Period 1 or Period 2</title>
          <description>Study participants received three doses of placebo first (Period 1) or second (Period 2 - after a twelve-week washout).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>E. coli pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospital admission for thymoglobulin infusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pedal edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Stiff neck</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Selim Arcasoy, MD</name_or_title>
      <organization>Columbia University Medical Cetner</organization>
      <phone>212-305-7771</phone>
      <email>sa2059@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

